Cabozantinib (CAS No: 849217-68-1; C28H24FN3O5 ; 501.51 g/mol) is a potent, orally bioavailable, multi-targeted tyrosine kinase inhibitor that suppresses tumor growth and angiogenesis by blocking critical signaling pathways such as VEGFR, MET, and RET. As a foundational therapeutic for advanced renal cell, hepatocellular, and medullary thyroid carcinomas, it requires rigorous analytical validation and comprehensive documentation for pharmaceutical research and development, which is expertly facilitated by Manasa Life Sciences, a trusted manufacturer and supplier based in Hyderabad, India. To ensure compliance with global regulatory standards—including ICH, EMA, USFDA, USP, and EP—the company provides high-quality support through advanced analytical characterization, including HPLC for purity profiling, Mass Spectrometry and LC-MS for molecular identification, and NMR for definitive structural elucidation. This technical infrastructure is supported by essential, fully compliant documentation packages—such as Certificate of Analysis (CoA), Material Safety Data Sheets (MSDS/SDS), and adherence to Good Manufacturing (GMP) and Distribution (GDP) practices—to maintain the integrity, safety, and regulatory readiness of the compound throughout its development lifecycle.